Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 12INDUSTRY 3NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Conditions

Psoriasis 4Lymphoma, Follicular 4Arthritis, Rheumatoid 3Pruritus 1Prostatic Neoplasms 1Plaque, Amyloid 1Bronchiolitis Obliterans Syndrome 1Bites and Stings 1Asthma 1Arthritis, Juvenile 1

Interventions

Methotrexate 10Adalimumab 6tocilizumab 5Rituximab 5olokizumab 4tofacitinib 3Etanercept 3golimumab 2RC-18 2Abatacept 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1baricitinib 1andecaliximab 1Tumor Necrosis Factor Inhibitors 1TACI receptor-IgG Fc fragment fusion protein 1Sulfasalazine 1Pharmaceutical Preparations 1Leflunomide 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1ISIS104838 1Hydroxychloroquine 1Folic Acid 1Double-Blind Method 1Chloroquine 1CT-P13 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Arthritis, Rheumatoid × Etanercept × Clear all
NCT02092467 2021-08-17

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

Pfizer

Phase 4 Completed
4,372 enrolled 22 charts

Arthritis, Rheumatoid

NCT00357903 2017-02-09

Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials

Amgen

Phase 3 Completed
639 enrolled 27 charts

Arthritis, Rheumatoid

NCT00724672 2015-06-01

A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)

Merck Sharp & Dohme LLC

Withdrawn

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡